Michael Germain
Nephrology · Springfield, MANPI 1376533117
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $314,421 of the $442,821 with a category attached, or 71.0%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2022 at $96,113 and has fallen 87.6% since, to $11,875 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $620.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$95K
- Vifor Pharma, Inc.$75K
- GSK$57K
- Calliditas Therapeutics US Inc.$51K
- Amgen$38K
- Veloxis Pharmaceuticals, Inc.$26K
- plus $102K from 22 others
Across 169 payments — averaging $3213.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$145K
- Bayer$103K
- Travere Therapeutics, Inc.$77K
- Vertex$42K
- Veloxis Pharmaceuticals, Inc.$36K
- OPKO Pharmaceuticals, LLC$34K
- plus $105K from 9 others
What the payments were for
- Consulting fees$84,58819%
- Speaking & faculty fees$314,42171%
- Travel & lodging$26,5046%
- Food & beverage$16,8514%
- Education$4570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 154 | $94,644 |
| Vifor Pharma, Inc. | 82 | $74,763 |
| GSK | 53 | $56,621 |
| Calliditas Therapeutics US Inc. | 55 | $50,625 |
| Amgen(2 entities) | 83 | $38,340 |
| Veloxis Pharmaceuticals, Inc. | 37 | $25,817 |
| Rockwell Medical, Inc. | 25 | $24,342 |
| Otsuka America Pharmaceutical, Inc. | 41 | $23,941 |
| Aurinia Pharma U.S., Inc. | 12 | $16,914 |
| Travere Therapeutics, Inc. | 27 | $13,444 |
| ANI Pharmaceuticals, Inc. | 51 | $9,714 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $7,274 |
| Akebia Therapeutics Inc | 5 | $2,413 |
| Novartis | 9 | $1,257 |
| OPKO Pharmaceuticals, LLC | 19 | $723 |
| Fresenius USA Marketing, Inc. | 7 | $537 |
| Alnylam Pharmaceuticals Inc. | 17 | $410 |
| Medtronic | 1 | $325 |
| Mallinckrodt Hospital Products Inc. | 6 | $236 |
| Bayer | 6 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Eurofins Viracor, LLC | 1 | $34 |
| Sanofi | 2 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Strongbridge US Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$442,821 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $55,719 |
| JardianceEmpagliflozin | 39 | $49,850 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $26,837 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $23,751 |
| Cinacalcet Hcl | 29 | $17,791 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,085 |
| Eplerenone | 16 | $5,121 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,077 |
| Valsartan | 19 | $1,110 |
| Spironolactone | 46 | $979 |
| Amlodipine Besylate | 125 | $932 |
| Losartan Potassium | 54 | $786 |
| Carvedilol | 54 | $781 |
| Metoprolol Succinate | 34 | $748 |
| Lisinopril | 55 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $94,644 | $79,47073 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $9,714 | $1,11019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 nephrology providers in Massachusetts.
Other nephrology in Springfield
- Jonathan SlaterSpringfield$83K
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
- Joshua HundertDorchester$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.